Open AccessImmunotherapy in Esophagogastric Adenocarcinoma
Author(s) -
Alexander Stein,
Peter ThussPatience
Publication year - 2019
Publication title -
visceral medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.598
H-Index - 17
eISSN - 2297-475X
pISSN - 2297-4725
DOI - 10.1159/000497292
Subject(s) - immunotherapy , esophagogastric junction , medicine , adenocarcinoma , oncology , chemotherapy , clinical trial , perioperative , refractory (planetary science) , disease , esophageal adenocarcinoma , surgery , cancer , biology , astrobiology
Immunotherapy, particular PD-1/L1 inhibition, is a relevant treatment approach in esophagogastric adenocarcinoma. To date, single-agent activity is limited to the chemotherapy refractory setting and molecularly defined subgroups. Currently, ongoing trials, which are likely to relevantly change the landscape of treatment for this disease in the next years, evaluate different combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. The German AIO study group has launched several combination trials in the perioperative, first-line, and advanced disease setting to further define the role of immunotherapy in esophagogastric adenocarcinoma.